Upadacitinib in refractory acquired reactive perforating collagenosis with atopic dermatitis and chronic kidney disease: a case report. (PubMed, Front Med (Lausanne)) - Oct 27, 2026 - "Here, we report a case of ARPC with concurrent AD in a patient with type 2 diabetes mellitus and stage 4 CKD, who experienced acute paradoxical exacerbation within 24 h of dupilumab initiation and achieved sustained remission with upadacitinib...Following two years of recurrent relapses despite systemic corticosteroids, antihistamines, and thalidomide, oral upadacitinib 15 mg once daily was initiated, with marked resolution of skin lesions and pruritus...This case suggests that upadacitinib is a promising salvage therapy for refractory ARPC, particularly after failure of Th2-targeted biologics. Its favorable safety profile at the standard dose without adjustment in stage 4 CKD supports its use in patients with complex comorbidities."
Journal • Atopic Dermatitis • Chronic Kidney Disease • Dermatitis • Dermatology • Diabetes • Gastrointestinal Disorder • Immunology • Metabolic Disorders • Nephrology • Pruritus • Renal Disease • Type 2 Diabetes Mellitus
|
|
Hao Lu; Juanjuan Liu; Lvyao Wang; Maolin Yao; Qing Wang; Xiangyu Hu; Xiao Qiu; Yuanfang Wan
|